CHIR-265 is a potent selective inhibitor of c-Raf/B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutations
Payman Amiri(Novartis (Switzerland)), Renhow Paul, Savithri Ramurthy(FuelCell Energy (United States)), Darrin D. Stuart(Scorpion Therapeutics (United States)), Barry H. Levine(Novartis (Switzerland)), Teresa E. Pick, Jeff Dove, Sharadha Subramanian(Novartis (Switzerland)), Mina Aikawa, Alex L. Harris, Abran Costales(Novartis (Switzerland)), Daniel Poon(Rapt Therapeutics (United States))
Cancer Research
April 15, 2006
Cited by 25
Related Papers
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
|Nature|2013|735
Attitudes and perceptions of UK medical students towards artificial intelligence and radiology: a multicentre survey
|Insights into Imaging|2020|492
Food, Shelter and Safety Needs Motivating Homeless Persons' Visits to an Urban Emergency Department
|Annals of Emergency Medicine|2008|100
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts
|Cancer Discovery|2023|67
A Missense Mutation in the MBTPS2 Gene Underlies the X-Linked Form of Olmsted Syndrome
|Journal of Investigative Dermatology|2012|57